SCT, secretin, 6343

N. diseases: 230; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE Importantly, the 7 cases of IA after allo- SCT occurred only in patients treated with corticosteroids for graft-versus-host disease (GVHD). 28689016 2019
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 GeneticVariation disease BEFREE Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59.5% vs. 30.8%, p = 0.05). 30747249 2019
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE The risk of acute graft-versus-host disease (GVHD) is significantly higher after HID-SCT versus ISD-SCT (OR = 1.88, 95% CI = 1.42-2.49, P < 0.00001), but the relapse rate is lower in HID-SCT group (OR = 0.70, 95% CI = 0.55-0.90, P = 0.005). 29381772 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. 30030270 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE Clinical options to restore immunocompetence after allogeneic-SCT are very limited as studies have raised awareness about the safety with regards to graft-versus-host disease (GVHD). 29967605 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE The purpose of the current review is to summarize the biology of GVHD and GVL responses in preclinical models and to discuss potential novel therapeutic strategies to reduce the relapse rate after allo-SCT. 30619371 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE We have compared prospectively the outcome and immune reconstitution of patients receiving either post-transplant cyclophosphamide (PTCY) (<i>n</i> = 30) or anti-thymocyte globulin ATG (<i>n</i> = 15) as Graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation (allo-SCT). 29545911 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE Haplo-SCT using a post-transplant cyclophosphamide-based regimen can achieve better leukemia-free survival and graft-versus-host disease-free, relapse-free survival, lower incidence of graft-versus-host disease and non-relapse mortality as compared to anti-thymocyte globulin-based graft-versus-host disease prophylaxis in patients with acute myeloid leukemia. 27758821 2017
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD. 24994916 2014
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE We also detected host-derived pro-inflammatory antigen-presenting cells (APCs) in skin GVHD lesions after allo-SCT. 23470132 2013
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.100 Biomarker disease BEFREE Donor lymphocyte infusions of HSV-tk represent a promising tool for preventing disease relapse and promoting immune reconstitution after haplo-SCT, and a unique tool for the control of GVHD. 12463592 2002